Tag: Drug Approvals
FDA Approves Zynyz as First-Line Treatment for Advanced Anal Cancer
The programmed death receptor-1-blocking antibody is approved as a single agent or in combination with chemotherapy
FDA Approves Zevaskyn for Rare, Genetic Skin Disorder
Zevaskyn is the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa
FDA Delays Final Approval of Novavax COVID Vaccine
FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia
Subcutaneous injection cuts the amount of the protein antithrombin, leading to an increase in thrombin
FDA Approves Cabozantinib for Previously Treated Advanced Neuroendocrine Tumors
Patients treated with cabozantinib survived significantly longer with no worsening of their disease compared with patients who received placebo
FDA Approves Blujepa for Uncomplicated Urinary Tract Infections
Medication approved for uUTIs in women and pediatric patients aged 12 years and older
FDA OKs Amvuttra to Treat Heart Conditions
FDA Approves Tremfya for Active Crohn Disease in Adults
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease
FDA Approves TNKase for Acute Ischemic Stroke
The five-second intravenous bolus offers faster, simpler administration than Activase
FDA Expands Indication of Dust Mite Allergy Drug to Include Young Children
Odactra is an immunotherapy for treatment of house dust mite-induced allergic rhinitis
